Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently, the clinical effectiveness of OV as monotherapy remains limited, and thus investigators have been exploring various...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhi, McGray, A. J. Robert, Jiang, Weijian, Lu, Binfeng, Kalinski, Pawel, Guo, Zong Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554963/
https://www.ncbi.nlm.nih.gov/pubmed/36221123
http://dx.doi.org/10.1186/s12943-022-01664-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554963/
https://www.ncbi.nlm.nih.gov/pubmed/36221123
http://dx.doi.org/10.1186/s12943-022-01664-z

Ejemplares similares